Bioresponsive Microneedle Patch for Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 20 December 2024 | Viewed by 120

Special Issue Editor

1. Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR 97213, USA
2. Department of Biomedical Engineering, School of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
Interests: drug delivery; bioresponsive materials; cancer immunotherapy

Special Issue Information

Dear Colleagues,

Bioresponsive microneedle patches represent an innovative approach that integrates the precision of microneedle technology with the responsive manner regarding biological conditions, offering a promising avenue for controlled and personalized medicines. With the painless microscopic needles penetrating the outer layer of the skin, these patches can effectively administer drugs at targeted sites, triggered by biomarkers such as pH, enzyme, and reactive oxygen species. This capability holds tremendous potential in treating various medical conditions, including chronic diseases, infections, cancers, and hormone regulations. The controlled release mechanism and the ability to tailor drug delivery to individual patients make this bioresponsive microneedle patch a cutting-edge solution, offering enhanced efficacy, reduced side effects, and improved patient compliance in the realm of pharmaceutical interventions.

The Special Issue’s goal is to capture the current progress in the field of bioresponsive microneedles that can be applied to different diseases with precisely controlled drug release and promising therapeutic outcomes.  

In this Special Issue, original research articles and reviews are welcome. Research areas may include, but are not limited to, transdermal drug delivery of small molecules, antibodies, hormones, or growth factors using bioresponsive microneedles for treating different diseases.

We look forward to receiving your contributions. 

Dr. Di Wen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microneedle
  • transdermal drug delivery
  • precise drug release
  • bioresponsive material
  • cancer immunotherapy

Published Papers

This special issue is now open for submission.
Back to TopTop